Citi initiated coverage on AbbVie Inc (NYSE: ABBV) Monday with a Sell rating and $48 price target. Analyst Andrew Baum felt that the market has underestimated the “timing and magnitude” of Humira ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results